The new drug, Nizi, has been approved for clinical study.

The new Class 6.1 drug, Nizili particles, developed by the Research Group of Aji Aiqbal Issa of the Xinjiang Institute of Science and Technology of the Chinese Academy of Sciences, received a clinical trial notice issued by the State Drug Administration on March 3 and agreed to conduct clinical trials.
grains originated from the classical clinical experience of Uyghur medicine, and consist of eight-flavored herbs such as Tianshan leeks, a branch of artemisinin, and hazelnuts.
plant Tianshan leeks, distributed in Xinjiang and other places, with wind and heat, detoxifying the effect of swelling.
the main treatment of cold fever,sores swollen, lymph nodes swollen.
particles have the function of removing the heat of nizi, clinically used for hot nizi to cause cold fever, cough, dry mouth, sore throat, nasal congestion, headache, fatigue, muscle soreness.
Naizi particles in accordance with the registration requirements of New Chinese Medicine, the research team completed all preclinical research work in pharmacy, pharmacy, toxicology, clinical program design, and carried out multiple batches of pilot research at the National Drug Key Technology and Process Engineering Research Center, comprehensive collection and analysis of new drug technology and engineering data, developed an industrialization process, and established a real-time quality control method for the production of new drugs.
major pharmacological studies have confirmed that nizile particles have good anti-inflammatory, cough-stopping sputum, pain relief and antibacterial antiviral effects in relevant animal models.
and long-term toxicity tests showed that it was safe to use drugs clinically.
Naizi grain has applied for a Chinese patent, and has won the 13th Five-Year Plan "major new drug creation" science and technology major special projects, major science and technology special projects in autonomous regions, the Chinese Academy of Sciences Institute of Drug Innovation independent deployment projects, the Chinese Academy of Sciences Youth Innovation Promotion Association and other funding.
()